Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways.
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hyun-Chang Kim, MD
- Phone Number: 82-10-2886-2876
- Email: onidori1979@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, Korea, Republic of
- Recruiting
- Seoul National University of Hospital
-
Principal Investigator:
- Hyun-Chang Kim, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients scheduled for transurethral bladder excision under general anesthesia
- ASA I-III
Exclusion Criteria:
- Foley catheter less than 18 Fr.
- Patients with obstruction of urinary tract
- Patients with neurogenic bladder
- Patients with severe obesity
- Patients with neurologic disorder
- Patients with chronic pain
- Patients with allergic history to atropine or glycopyrrolate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Glycopyrrolate
Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
|
Glycopyrrolate will be administered.
|
|
Active Comparator: Atropine
Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
|
Atropine will be administered.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Catheter-related bladder discomfort
Time Frame: 1 hour postoperatively
|
Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).
|
1 hour postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Catheter-related bladder discomfort
Time Frame: 0, 6 and 24 hour postoperatively
|
Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).
|
0, 6 and 24 hour postoperatively
|
|
Hemodynamic parameters
Time Frame: 0, 1, 5, 10 minute postoperatively
|
Mean blood pressure and heart rate will be measured at 0, 1, 5, 10 minute postoperatively.
Measurement at 10 minute means Mean blood pressure and heart rate at the admission of post-anesthetic care unit.
|
0, 1, 5, 10 minute postoperatively
|
|
Nausea
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Nausea will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Vomiting
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Vomiting will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Dry mouth
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Dry mouth will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Flushing
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Flushing will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Blurred vision
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Blurred vision will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Dizziness
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Dizziness will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Analgesics
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
The amount of analgesics will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hee-Pyoung Park, PhD, Seoul National University of Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Mydriatics
- Glycopyrrolate
- Atropine
Other Study ID Numbers
Other Study ID Numbers
- CRBDGlycoAtr
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.